{"brief_title": "SU011248 In The Treatment Of Patients With Bevacizumab (Avastin)-Refractory Metastatic Renal Cell Carcinoma", "brief_summary": "The purpose of this study is to test whether sunitinib (SU011248) has activity and is safe in patients with renal cell carcinoma (RCC) who have failed prior therapy with bevacizumab (Avastin) -based treatment.", "condition": ["Carcinoma, Renal Cell"], "intervention_type": ["Drug"], "intervention_name": ["Sunitinib"], "description": ["50 mg orally daily for 4 weeks followed by 2 weeks off treatment for approximately 1 year or until disease progression/unacceptable toxicity; after completion of 1 year, pts with clinical benefit can continue the study treatment in a separate continuation protocol"], "arm_group_label": ["1"], "other_name": ["SUTENT, SU011248,"], "criteria": "Inclusion Criteria: - Histologically proven renal cell carcinoma of clear cell histology with metastases - Evidence of measurable disease - Radiographic evidence of disease progression during or within 3 months of completion of bevacizumab-based treatment - Prior radical or partial nephrectomy Exclusion Criteria: - Prior treatment with any other anti-angiogenic therapy other than bevacizumab - Prior systemic treatment for RCC > 2 regimens - History of or known brain metastases - Serious acute or chronic illness or recent history of significant cardiac abnormality", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "mesh_term": ["Carcinoma", "Carcinoma, Renal Cell", "Bevacizumab", "Sunitinib"], "id": "NCT00089648"}